Skip to search formSkip to main contentSkip to account menu

HuMax-CD20

Known as: HuMax-CD20 monoclonal antibody, MOAB HuMax-CD20, monoclonal antibody HuMax-CD20 
National Institutes of Health

Related topics

Related topics

1 relation
ofatumumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
Enhanced AXL expression has been observed in tumor tissues obtained from non-small cell lung (NSCLC) patients, both in drug… 
2017
2017
GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors…
TPS2605Background: HuMax-AXL-ADC is an antibody-drug conjugate (ADC) composed of an Axl-specific human monoclonal immunoglobulin… 
2017
2017
Abstract 4591: Specific elimination of invasive and multidrug-resistant cancer cells by an antibody-drug conjugate targeting AXL
Upon therapeutic pressure, cancers commonly select for drug-resistant, invasive subpopulations with elevated expression of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)